US Stock Market Closed

Dashboard

Moderna, Inc. (MRNA)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

B

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

CEO

Stéphane Bancel

Employees

830

Industry

Infectious Disease Biopharmaceuticals

Sector

Healthcare

Headquarters

Cambridge

Exchange

NASDAQ

Summary Stats

Market Cap

67.8B

Revenue

21.4B

Net Income

11.8B

EPS

$27.91

Price-to-Earnings

6.32

Price-to-Book

3.77

Debt-to-Equity

0.45

News

Analyst Ratings

Price targets projected by 15 analysts

High

$166.00

Average

$112.87

Low

$60.00

Ratings calculated by 17 analysts

Buy

11

Hold

4

Sell

2

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Missed by -$0.76

Actual

$2.53 -23.1%

Consensus

3.29

Report Date

Year Ago

7.7

Year Ago Change %

Down 67%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites